Poseida Therapeutics Inc
NASDAQ:PSTX

Watchlist Manager
Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc
NASDAQ:PSTX
Watchlist
Price: 2.73 USD 0.74% Market Closed
Market Cap: 266.1m USD
Have any thoughts about
Poseida Therapeutics Inc?
Write Note

Intrinsic Value

PSTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PSTX stock under the Base Case scenario is 0.87 USD. Compared to the current market price of 2.73 USD, Poseida Therapeutics Inc is Overvalued by 68%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PSTX Intrinsic Value
0.87 USD
Overvaluation 68%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Poseida Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PSTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PSTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Poseida Therapeutics Inc

Provide an overview of the primary business activities
of Poseida Therapeutics Inc.

What unique competitive advantages
does Poseida Therapeutics Inc hold over its rivals?

What risks and challenges
does Poseida Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Poseida Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Poseida Therapeutics Inc.

Provide P/S
for Poseida Therapeutics Inc.

Provide P/E
for Poseida Therapeutics Inc.

Provide P/OCF
for Poseida Therapeutics Inc.

Provide P/FCFE
for Poseida Therapeutics Inc.

Provide P/B
for Poseida Therapeutics Inc.

Provide EV/S
for Poseida Therapeutics Inc.

Provide EV/GP
for Poseida Therapeutics Inc.

Provide EV/EBITDA
for Poseida Therapeutics Inc.

Provide EV/EBIT
for Poseida Therapeutics Inc.

Provide EV/OCF
for Poseida Therapeutics Inc.

Provide EV/FCFF
for Poseida Therapeutics Inc.

Provide EV/IC
for Poseida Therapeutics Inc.

Show me price targets
for Poseida Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Poseida Therapeutics Inc?

How accurate were the past Revenue estimates
for Poseida Therapeutics Inc?

What are the Net Income projections
for Poseida Therapeutics Inc?

How accurate were the past Net Income estimates
for Poseida Therapeutics Inc?

What are the EPS projections
for Poseida Therapeutics Inc?

How accurate were the past EPS estimates
for Poseida Therapeutics Inc?

What are the EBIT projections
for Poseida Therapeutics Inc?

How accurate were the past EBIT estimates
for Poseida Therapeutics Inc?

Compare the revenue forecasts
for Poseida Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Poseida Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Poseida Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Poseida Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Poseida Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Poseida Therapeutics Inc with its peers.

Analyze the financial leverage
of Poseida Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Poseida Therapeutics Inc.

Provide ROE
for Poseida Therapeutics Inc.

Provide ROA
for Poseida Therapeutics Inc.

Provide ROIC
for Poseida Therapeutics Inc.

Provide ROCE
for Poseida Therapeutics Inc.

Provide Gross Margin
for Poseida Therapeutics Inc.

Provide Operating Margin
for Poseida Therapeutics Inc.

Provide Net Margin
for Poseida Therapeutics Inc.

Provide FCF Margin
for Poseida Therapeutics Inc.

Show all solvency ratios
for Poseida Therapeutics Inc.

Provide D/E Ratio
for Poseida Therapeutics Inc.

Provide D/A Ratio
for Poseida Therapeutics Inc.

Provide Interest Coverage Ratio
for Poseida Therapeutics Inc.

Provide Altman Z-Score Ratio
for Poseida Therapeutics Inc.

Provide Quick Ratio
for Poseida Therapeutics Inc.

Provide Current Ratio
for Poseida Therapeutics Inc.

Provide Cash Ratio
for Poseida Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Poseida Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Poseida Therapeutics Inc?

What is the current Free Cash Flow
of Poseida Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Poseida Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Poseida Therapeutics Inc

Current Assets 250.7m
Cash & Short-Term Investments 230.9m
Receivables 14.7m
Other Current Assets 5.1m
Non-Current Assets 42.9m
PP&E 36.4m
Intangibles 5.5m
Other Non-Current Assets 905k
Current Liabilities 78.3m
Accounts Payable 5.2m
Accrued Liabilities 31.5m
Other Current Liabilities 41.6m
Non-Current Liabilities 128.1m
Long-Term Debt 58.9m
Other Non-Current Liabilities 69.2m
Efficiency

Earnings Waterfall
Poseida Therapeutics Inc

Revenue
150.9m USD
Operating Expenses
-213.4m USD
Operating Income
-62.5m USD
Other Expenses
1.7m USD
Net Income
-60.8m USD

Free Cash Flow Analysis
Poseida Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PSTX Profitability Score
Profitability Due Diligence

Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

PSTX Solvency Score
Solvency Due Diligence

Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
44/100
Solvency
Score

Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PSTX Price Targets Summary
Poseida Therapeutics Inc

Wall Street analysts forecast PSTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PSTX is 14.28 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

Lowest
Price Target
10.1 USD
270% Upside
Average
Price Target
14.28 USD
423% Upside
Highest
Price Target
21 USD
669% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PSTX?

Click here to dive deeper.

Dividends

Poseida Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PSTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PSTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

265.9m USD

Dividend Yield

0%

Description

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).

Contact

CALIFORNIA
San Diego
9390 Towne Centre Drive, Suite 200
+18587793100.0
poseida.com

IPO

2020-07-10

Employees

263

Officers

Executive Chairman of the Board
Mr. Mark J. Gergen J.D.
President, CEO & Director
Dr. Kristin Yarema Ph.D.
Chief Financial Officer
Ms. Johanna M. Mylet CPA
Chief Operations Officer
Mr. Loren Wagner
Chief People & Administration Officer
Ms. Kristin Martin
Senior VP of Investor Relations & Corporate Communications
Mr. Alexander Chapman
Show More
General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. Harry J. Leonhardt Esq., J.D.
Chief Scientific Officer of Cell Therapy
Dr. Devon J. Shedlock Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Lisa Portale
Senior VP & Chief Patent Counsel
Dr. Jeffrey W. Winkelman J.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one PSTX stock?

The intrinsic value of one PSTX stock under the Base Case scenario is 0.87 USD.

Is PSTX stock undervalued or overvalued?

Compared to the current market price of 2.73 USD, Poseida Therapeutics Inc is Overvalued by 68%.

Back to Top